Get started
Author

Patrick N.A. Bronzwaer

Observed names: P Bronzwaer, P N A Bronzwaer, P. Bronzwaer, P. N.A. Bronzwaer, PATRICK BRONZWAER, Patrick Bronzwaer, Patrick N A Bronzwaer, Patrick NA Bronzwaer
OpenAlex ID: A5111716915
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 315
PDF
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Gregory G. Schwartz, Gregory G. Schwartz, et al. · Journal of the American College of Cardiology · 148
PDF
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 118
PDF
Nurse-led vs. usual-care for atrial fibrillation
2019 · E P J Petra Wijtvliet, Robert G Tieleman, et al. · European Heart Journal · 115
PDF
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40
PDF
Trimetazidine in Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Cross-Over Trial
2023 · Arno A. van de Bovenkamp, Kiki T. J. Geurkink, et al. · ESC Heart Failure · 38
PDF
The BRIGHT study: bifocal right ventricular resynchronization therapy: a randomized study
2007 · J. C.J. Res, M. J.J.A. Bokern, et al. · EP Europace · 28
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 26
PDF
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 25
PDF
Rate control drugs differ in the prevention of progression of atrial fibrillation
2021 · Tim Koldenhof, Petra E P J Wijtvliet, et al. · EP Europace · 25
PDF
Pneumothorax resulting from subclavian puncture: a complication of permanent pacemaker lead implantation.
2004 · J C J Res, J A de Priester, et al. · PubMed · 25
Rate control drugs differ in the prevention of progression of atrial fibrillation
2020 · T Koldenhof, E.P.J.P Wijtvliet, et al. · European Heart Journal · 4
Long-term follow-up of 100 patients with left anterior descending artery lesions treated with percutaneous transluminal coronary angioplasty
1989 · H. Bonnier, P. Bronzwaer, et al. · European Heart Journal · 3
Previous Exercise Levels and Outcome in Patients with New Atrial Fibrillation: “Past Achievements Do Not Predict the Future”
2024 · CHARLOTTE J. LENTING, E. P. J. PETRA WIJTVLIET, et al. · Medicine & Science in Sports & Exercise · 2
Works count: 14
Citation count: 911
H-index: 11
I10-index: 11
Year
Topic
Type